ADVANCED PROTEOME THERAPEUTICS ADVANCES ITS TECHNOLOGICAL CAPABILITY

Vancouver, British Columbia / June 18, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs).

Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a significant factor that often requires outsourcing to other companies at considerable cost and down time. APC can now report that it has achieved a breakthrough in processing development candidates for scale up that will allow the Company to independently supply its partners with material.

The new modified protocol has enabled APC to progress collaborative programs as with Heidelberg Pharma (HDP) (Marketwired – January 08, 2018) by producing scaled-up amounts of antibody-drug conjugates with our proprietary, time-dependent, site-selective linking process. The Company can now handle the additional capacity necessary for animal testing, without resort to outsourcing and provide the requisite amounts of material at modest cost.

 

Allen Krantz, Chief Scientific Officer of APC, stated that “Our progress in reducing the volumes that required specialized equipment for purifying ADCs will facilitate technology transfer to our partners. The promising cytotoxicity studies that we announced in January provided the impetus for successfully scaling up our conjugative processes to accept a far larger scope of material necessary for the testing of potency and toxicity on animal subjects, which we are proud to have achieved in-house. For example, this technological advance has allowed us to efficiently produce samples for the HDP collaboration, which has now entered the animal phase of testing.”

ABOUT THE COMPANY:

Advanced Proteome Therapeutics Corporation is developing a proprietary technology to directly target cancerous tumors and avoid destroying normal cells.  This type of agent is capable of greater potency, higher specificity and lower toxicity than other therapies that can also attack healthy cells.  The Company is working to streamline the process by which these agents are prepared, which to date, has been extremely cumbersome, limiting their potential.

FOR FURTHER INFORMATION PLEASE CONTACT:

Advanced Proteome Therapeutics Corporation
Bill Dickie

President and CEO
Tel: 617 358-9777
http://www.advancedproteome.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

 

2018-06-27T11:25:17+00:00